Standards, data integrity, and traceability may not grab headlines, but they quietly determine whether a healthcare system can be trusted. The GS1 India Healthcare Conference 2026, held under the theme “The Next Frontier in Healthcare: Standardised, Sustainable & Safe,” placed these foundations at the centre of the conversation and DCVMN CEO Rajinder Suri joined to carry the perspective of developing-country vaccine manufacturers into the discussion.
The programme opened with the Inaugural Session, “Building a Standardised, Sustainable & Safe Healthcare Ecosystem,” which set the strategic context for the day. Following the welcome by Mr. Sachidanantham Swaminathan, CEO of GS1 India, and the keynote delivered by Dr. Chandrashekar Ranga, Joint Drugs Controller (India), CDSCO, Mr. Suri delivered a Special Address alongside Dr Amit Talwar, Associate Secretary General of the Indian Pharmaceutical Alliance, and Mr. Sandeep J., Partner Healthcare at KPMG India. The session highlighted the need for a patient-centric healthcare ecosystem supported by the organisational readiness that standards adoption, strong data integrity, and end-to-end visibility require.
Mr. Suri later took part in the panel discussion “Navigating Regulatory Challenges in a Rapidly Evolving Pharma Landscape,” moderated by Mr. Dishant Budhrani, Partner at Deloitte India, and panelists Mr. Sudhakar Mairpady, Director of Regulatory Affairs & Government Affairs at Becton Dickinson, Dr. Priya Chatterjee, Head Regulatory Affairs South Asia at Bayer | Pharmaceuticals, and Mr. Abhijeet Ashok Gujar, Compliance and Regulatory Head at Roche. The conversation explored how regulators and industry can keep pace with innovation without compromising quality or safety.
Speaking from the DCVMN perspective, Mr. Suri brought three threads into the discussion. First, how regulators can structure the balance between enabling rapid access to life-saving vaccines and upholding the highest standards of quality and safety across developing countries. Second, the lessons that the global vaccine ecosystem offers for strengthening health supply chains across emerging markets. And third, that the most durable and effective regulatory frameworks are built through collaboration, with industry, regulators, and global health organisations working together to design regulations that are not only well-intentioned, but implementable in practice.
Conversations like these are part of the fabric of DCVMN’s broader advocacy work, ensuring that the perspective of developing-country vaccine manufacturers is present wherever the standards, systems, and partnerships shaping tomorrow’s healthcare are being discussed.
